Background. Transplant recipients are at risk for invasive aspergillosis (IA), associated with a significant mortality rate. Renal transplant-specific risk factors have not been established.
Although Aspergillus spores are ubiquitous in nature, invasive infection is uncommon, and occurs most frequently in the setting of immunosuppression associated with therapy for hematologic malignancies, hematopoietic stem cell transplant (HSCT), or solid organ transplant (SOT) [1] . The relative incidence in liver, lung, and heart transplant seems to outnumber the incidence in renal transplant [1, 2] . This has been partly explained by the healthier preoperative state of renal transplant recipients [2] .
The largest cohort of renal transplant recipients who developed invasive aspergillosis (IA) has been described by Baddley et al and included 47 cases [3] . This study was a case series as no risk factors were described. To the best of our knowledge, the largest study investigating specific risk factors in SOT included only 10 renal transplant recipients [4] .
As IA is associated with a significant crude mortality rate [3, 5] , a better understanding of the risk factors and prognostic factors are of importance, to guide preventive measures, diagnostic workup, and therapeutic decisions.
PATIENTS AND METHODS

Study Patients
This retrospective study included all patients who underwent renal transplant at the University Hospitals Leuven, Belgium. Adult kidney transplant recipients diagnosed with IA from 1995 through 2013 were identified in the computerized patient files. Patient data were collected from a prospectively maintained database and by additional chart review. Day of diagnosis was defined as the first day of antifungal therapy. Cases of IA were classified according to Hope et al [6] and as "probable" or "proven" according to the revised standard criteria from the European Organization for Research and Treatment of Cancer-Mycoses Study Group [7] . The control population in this 1:2 case-control study consisted of the 2 patients who underwent kidney transplant immediately before and after each identified patient and did not develop IA.
Kidney Transplant Protocols: Immunosuppression and Prophylactic Measures
The immunosuppressive regimen varied according to the time period, with cyclosporine and azathioprine being largely replaced by tacrolimus and mycophenolate mofetil from 1999 onward. Only 6 patients (3 cases and 3 controls) received an mTor inhibitor (sirolimus), whereas all patients received corticosteroids. Induction therapy (antithymocyte globulin or anti-interleukin 2 receptor antibodies) was given to highly immunized recipients ( panel reactive antibody >30%, North African origin, second or subsequent transplantation) and recipients of living donation [8] since 1995. Rejection episodes were treated with methylprednisolone in a tapering regimen. In patients undergoing transplant after 1998, prophylaxis against cytomegalovirus (CMV) infection with ganciclovir was given when recipient and/or donor were CMV seropositive. Pneumocystis jirovecii infection prophylaxis with trimethoprim-sulfamethoxazole was given to all patients in the first 3 months following transplant. No systemic antifungal prophylaxis was used.
Diagnostic Testing
Physical examination, chest radiography, and/or chest computed tomography and blood cultures were performed in all febrile patients at clinical suspicion of infection. Additional samples for culture were obtained as clinically indicated. Tissue and bronchoalveolar lavage (BAL) fluid samples were evaluated for the presence of fungi by use of standard histopathologic and microbiological techniques. Since 1999, the Platelia Aspergillus galactomannan enzyme immunoassay was performed on serum samples when a diagnosis of IA was suspected. Since 2003, it was performed on BAL samples as well. A galactomannan index of ≥0.5 was used to define positivity, both in serum and BAL [9, 10] .
Treatment Regimens for Invasive Aspergillosis
Before 2003, amphotericin B products were administered as standard therapy. Since 2003, voriconazole became the drug of choice. Caspofungin was used in 4 patients and posaconazole in 1 patient, due to voriconazole intolerance/toxicity or due to coinfection with resistant fungi.
Data Analysis
The primary objective of the study was to determine the risk factors in kidney transplant recipients by performing a casecontrol study. We included the following recipient variables: age, sex, duration of renal replacement therapy (for second and subsequent transplants, the duration after failure of the previous transplant was used), smoking habits, preexisting chronic lung disease, diabetes mellitus prior to transplant, respiratory function measured as part of the pretransplant workup, total number of human leukocyte antigen [HLA] mismatch, use of basiliximab or antithymocyte globulin, donor and/or recipient CMV seropositivity and its prophylaxis, and the occurrence of leukopenia (<3000/µL) and acute rejection after transplant. Results from the obtained cultures and biopsies were described, in addition to the galactomannan optical density index on serum and BAL samples. The use of specific immunosuppressive drugs could not be included as variable for risk factor analysis, because of time-related changes in the patients' immunosuppressive regimen. Recipients who developed IA before month 3 after transplant were analyzed separately as "early IA," and the recipients with IA after month 3 as "late IA" in concordance with previous studies [4, 11] . Continuous data were expressed as the mean ± standard deviation and 95% confidence interval [CI] , for normally distributed data and as median and interquartile range (IQR) for skewed data. Discrete variables were expressed as percentages. Continuous variables were compared using Student unpaired t test or the Mann-Whitney U test, where appropriate. Proportions were compared using the χ 2 test or the Fisher exact test. Odds ratios (ORs)
were calculated by univariate binary logistic regression analysis. The secondary objective of this study was to determine the prognostic factors of IA after kidney transplant. Mortality at week 12 after diagnosis was used as an endpoint in concordance with other studies [3, 12] . For the mortality analyses, the same host variables were included, but instead of leukopenia after transplant, leukopenia (<3000/µL) at the time of presentation with the infection was included.
Survival at week 12 after diagnosis was estimated with KaplanMeier curves and compared between groups using log-rank P values. Hazard ratios (HRs) were calculated by univariate Cox proportional hazards analysis. All statistical tests were 2-tailed, and the threshold of statistical significance was P < .05.
RESULTS
Clinical Presentation
Forty-one cases of IA after kidney transplant were identified between 1995 and 2013: 24 men and 17 women, with a mean age of 61 ±12 years at diagnosis. Eleven patients had leukopenia at presentation (27%), and 7 patients (17%) had a CMV infection prior or during the infection with Aspergillus. Other patient characteristics are summarized in Table 1 .
The distribution of IA episodes according to the time of diagnosis after transplant is presented in Figure 1 . The median time to the development of IA was 141 days (IQR, 72-522 days). Fifteen recipients (37%) developed early IA, and 26 recipients (63%) developed late IA. The infection was proven IA in 18 recipients (44%) and probable IA in 23 recipients (56%). Five cases developed disseminated infection (ie, with involvement of ≥2 noncontiguous organs). Four of these presented with symptoms of invasive pulmonary aspergillosis, and 1 presented with an intraocular infection. All patients with disseminated IA died. In 4, myocardial aspergillosis could be identified postmortem. In all cases with positive cultures (38 from 41 patients), Aspergillus fumigatus was identified as the pathogen. In 1 case, there was a coinfection with Aspergillus niger. From the 36 patients with localized IA, 30 had invasive pulmonary aspergillosis, 4 had invasive bronchial aspergillosis, 1 had cerebral abscess, and 1 had acute invasive sinusitis extending to the mastoid bone and cerebrum. In the 34 patients with IA of the lower respiratory tract, positive cultures could be obtained in 10 of 22 sputum samples, 14 of 22 bronchus aspirate samples, 17 of 27 BAL samples, 0 of 6 pleural fluid samples, and 3 of 4 bronchus biopsy samples. Microscopy of bronchus aspirate or BAL fluid could demonstrate fungal hyphae in 2 of 12 samples. The galactomannan index was positive in 14 of 15 BAL fluid samples (mean index, 3.9 ± 2.5). In the total patient cohort, the galactomannan index was positive in 11 of 33 serum samples (mean index, 1.6 ± 2.9).
Risk Factors
The occurrence of leukopenia after transplant increased the risk of IA (OR, 2.345 [95% CI, 1.084-5.071]; P = .029), whereas smoking status, sex, age, diabetes mellitus prior to transplant, chronic lung disease, duration of renal replacement therapy prior to transplant, total number of HLA mismatch, presence of HLA antibodies, use of induction therapy or CMV prophylaxis, poor respiratory function tests prior to transplant, the occurrence of CMV infection, and acute rejection did not (Table 1) .
Recipients with early IA had a significantly longer duration of renal replacement therapy before transplant compared with controls (median, 3.57 [IQR, 2.02-5.15] years vs median, 2.04 [IQR, 1.22-3.05] years; P = .019). Leukopenia in the first 3 months after transplant was also associated with early IA (47% vs 21%; P = .049). In contrast, the duration of renal replacement therapy before transplant did not differ between patients with late IA and the controls (median, 1.48 [IQR, 1.09-3.51] years vs median, 2.04 [IQR, 1.22-3.05] years; P = .808). The occurrence of leukopenia was not a significant risk factor for late IA (54% vs 21%; P = .119). CMV positivity of the donor increased the risk of late IA (61% vs 29%; P = .007). There was a trend for increased risk with seropositivity of the recipient (71% vs 47%; P = .051), whereas CMV prophylaxis (50% vs 39%; P = .323) and CMV infection (23% vs 15%; P = .367) did not increase the risk. There was also a trend for increased risk of late IA for recipients with a chronic respiratory disease (19% vs 6%; P = .058) ( Table 2) . Figure 2 ). Using the receiver operating characteristic curve and Youden statistic, the optimal cutoff for the serum galactomannan level to predict the risk for death was an index of 2.0. Figure 2 . There was a trend toward increased mortality according to smoking status (Table 3) .
DISCUSSION
Over the past decade, risk factors for SOT-associated IA and its prognostic factors have been identified [3, 4] , and this has improved early diagnosis and treatment [13] [14] [15] [16] . The relatively lower incidence among kidney transplant recipients compared with other organ transplant recipients explains the lack of studies focusing on IA in this population. By comparing 41 cases with 82 noninfected recipients, transplanted immediately before and after each case, we could identify risk factors specific for kidney transplant recipients. The risk of IA early after transplant increased with prolonged renal replacement therapy before transplant. In SOT in general, renal failure and the need of renal replacement therapy after transplant are independent risk factors for IA [4] . In liver transplant recipients, it is one of the most significant risk factors for IA, leading to a 15-to 25-fold greater risk [17, 18] . Our results demonstrate for the first time an increased susceptibility with longer duration of renal replacement therapy before transplant.
Similar to previous studies in SOT, leukopenia increased the risk for IA [4] . We chose a less strict definition of leukopenia compared to studies in hematology to determine risk factors specific for the transplant setting. This is in agreement to a similar case-control study on IA in SOT [4] . The retrospective design of this study precluded us from obtaining information about the duration of leukopenia.
There was a trend toward increased risk for late IA in recipients with a chronic respiratory disease. Others have previously suggested an association between respiratory dysfunction and risk of IA, as patients with chronic obstructive pulmonary disorder are at risk of invasive pulmonary aspergillosis and their increased susceptibility does not seem to be explained by exposure to steroids alone [5, [19] [20] [21] .
In line with previous reports [22] , we did not find an association between acute rejection and the occurrence of IA. We did find an association between donor CMV positivity and the risk for late IA, similar to what has been observed in liver transplant recipients [23] . CMV infection is known to induce an immunosuppressed state [24] , and its therapy can induce leukopenia. In liver transplant recipients, CMV disease is associated with invasive fungal disease [23] . In our cohort, 17% of cases had a CMV infection immediately prior to or during the infection with Aspergillus. However, the occurrence of CMV infections after transplant was not significantly higher compared with the control group.
The overall 12-week mortality of 39% is lower than the mortality previously described among HSCT and transplant patients [5, 25] , but comparable to a more recent study in SOT [3] . Mortality decreased after 2002, when voriconazole was introduced in our therapy regimens. The prognostic effect of this time point was more pronounced than the effect of treatment regimens including voriconazole. However, this study was not designed to investigate the prognostic role of a specific antifungal therapy. In addition, many patients received subsequently different regimens, for example, due to renal function deterioration.
Patients with leukopenia at presentation had an increased risk of death. A higher case fatality rate in patients with neutropenia has already been observed [5] , but has not been reported for SOT recipients specifically [4] . In addition, the height of the serum galactomannan test correlated with mortality, whereas the BAL galactomannan did not. This is in agreement with what has been reported in HSCT patients [26] and patients with hematologic cancer [27] . We are the first to describe this association in SOT recipients. In contrast, the serum galactomannan test lacks sensitivity for IA diagnosis in SOT recipients, whereas the sensitivity of the galactomannan test in BAL fluid is high in this population [16, 28, 29] . The higher serum galactomannan level is thought to represent a higher Aspergillus burden and/or increased micro-or macro-dissemination [26] . In our cohort, disseminated IA increased the risk of death, similar to what has been reported elsewhere [3, 12, 25] .
We could not observe an association between the respiratory function measured pretransplant and mortality after IA. In a study of HSCT patients, a compromised respiratory function pretransplant was the only host factor independently associated with an increased risk for death, but the criteria used to define severe pulmonary function abnormality were not reported in this study [25] .
The strength of our study is the relatively large case cohort among kidney transplant recipients compared to other studies, the focus on kidney transplant alone, and the inclusion of only proven and probable cases. However, the number of cases was too low to perform accurate multivariate testing. In addition, the retrospective design in this large time frame precluded the collection of all variables in all patients.
In conclusion, the duration of renal replacement therapy and the occurrence of leukopenia increased the risk for early IA after kidney transplant. Mortality rate was highest among recipients with leukopenia, disseminated infection, and higher levels of serum galactomannan test.
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